ArticleCost effectiveness and resource allocation : C/E2023

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.

Hongyu Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.